Preserved skeletal muscle protein anabolic response to acute exercise and protein intake in well-treated rheumatoid arthritis patients

Mikkelsen, Ulla Ramer; Dideriksen, Kasper; Andersen, Mads Bisgaard; Boesen, Anders; Malmgaard-Clausen, Nikolai Mølkjær; Sørensen, Inge Juul; Schjerling, Peter; Kjær, Michael; Holm, Lars

DOI: 10.1186/s13075-015-0758-3

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Mikkelsen, UR, Dideriksen, K, Andersen, MB, Boesen, A, Malmgaard-Clausen, NM, Sørensen, IJ, Schjerling, P, Kjær, M & Holm, L 2015, 'Preserved skeletal muscle protein anabolic response to acute exercise and protein intake in well-treated rheumatoid arthritis patients', Arthritis Research & Therapy, vol. 17, 271. https://doi.org/10.1186/s13075-015-0758-3

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 15. Jul. 2021
Preserved skeletal muscle protein anabolic response to acute exercise and protein intake in well-treated rheumatoid arthritis patients

Ulla Ramer Mikkelsen¹,²*, Kasper Dideriksen¹, Mads Bisgaard Andersen¹, Anders Boesen¹, Nikolai Mølkjær Malmgaard-Clausen¹, Inge Juul Sørensen³, Peter Schjerling¹, Michael Kjær¹ and Lars Holm¹,⁴

Abstract

Introduction: Rheumatoid arthritis (RA) is often associated with diminished muscle mass, reflecting an imbalance between protein synthesis and protein breakdown. To investigate the anabolic potential of both exercise and nutritional protein intake we investigated the muscle protein synthesis rate and anabolic signaling response in patients with RA compared to healthy controls.

Methods: Thirteen RA patients (age range 34–84 years; diagnosed for 1–32 years, median 8 years) were individually matched with 13 healthy controls for gender, age, BMI and activity level (CON). Plasma levels of C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α were measured using enzyme-linked immunosorbent assay (ELISA) in resting blood samples obtained on two separate days. Skeletal muscle myofibrillar and connective tissue protein fractional synthesis rate (FSR) was measured by incorporation of the amino acid ¹³C₆-phenylalanine tracer in the overnight fasted state for 3 hours (BASAL) and 3 hours after intake of whey protein (0.5 g/kg lean body mass) alone (PROT, 3 hrs) and in combination with knee-extensor exercise (EX) with one leg (8 × 10 reps at 70 % of 1RM; PROT + EX, 3 hrs). Expression of genes related to inflammatory signaling, myogenesis and muscle growth/atrophy were analyzed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR).

Results: CRP was significantly higher in the RA patients (2.25 (0.50) mg/l) than in controls (1.07 (0.25) mg/l; p = 0.038) and so was TNF-α (RA 1.18 (0.30) pg/ml vs. CON 0.64 (0.07) pg/ml; p = 0.008). Muscle myofibrillar protein synthesis in both RA patients and CON increased in response to PROT and PROT + EX, and even more with PROT + EX (p < 0.001), with no difference between groups (p > 0.05). The gene expression response was largely similar in RA vs. CON, however, expression of the genes coding for TNF-α, myogenin and HGF1 were more responsive to exercise in RA patients than in CON.

Conclusions: The study demonstrates that muscle protein synthesis rate and muscle gene expression can be stimulated by protein intake alone and in combination with physical exercise in patients with well-treated RA to a similar extent as in healthy individuals. This indicates that moderately inflamed RA patients have maintained their muscle anabolic responsiveness to physical activity and protein intake.

* Correspondence: ullaramer@hotmail.com

¹Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Hospital bldg 8, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark

²Section for Sports Science, Institute of Public Health, Aarhus University, Dalgas Avenue 4, 8000 Aarhus C, Denmark

Full list of author information is available at the end of the article

© 2015 Mikkelsen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Introduction**

Rheumatoid arthritis (RA) is a systemic, inflammatory, autoimmune disease primarily affecting the joints [1]. Patients with RA are often characterized by having a lower muscle mass than their peers [2] and one of the causal mechanisms has been suggested to be related to the chronic inflammatory state [3]. Rat studies show that the development of low-grade inflammation negatively affects muscle mass and attenuates the muscle protein synthesis response to feeding [4, 5]. Moreover, plasma from cachectic patients (cancer and septic shock), characterized by high levels of inflammatory markers, can induce inflammatory signaling and loss of muscle protein in cultured muscle cells [6–8]. Likewise, an increased level of systemic inflammation may contribute to the muscle loss observed in relation to other diseases like cancer, chronic obstructive pulmonary disease (COPD) and diabetes [8–15]. Evidently, the loss of muscle mass leads to muscle strength deficits and in addition, RA patients may have reduced muscle strength due to greater intramuscular fat infiltration [16] along with pain-related limitations. In addition to the repeatedly reported reductions in muscle strength in RA patients [16–18], metabolic changes occur in both preclinical and later RA stages, including deterioration of blood lipid profile and insulin sensitivity [19–21] which may increase cardiovascular disease risk, summing up to a reduced life span [22]. All of these conditions could be rejuvenated by improving skeletal muscle mass and quality by means of exercise and nutritional interventions, highlighting the importance of understanding the molecular regulation of muscle mass in RA.

Resistance exercise enhances protein turnover rate, thus increases both protein synthesis and breakdown rates. However, a concomitant intake of dietary protein further stimulates muscle protein synthesis resulting in a net protein synthesis and thus protein accretion. When repeated, it makes up a strategy to counteract loss of muscle mass and strength.

In the present study, we aimed to investigate skeletal muscle mass regulation in methotrexate-treated RA patients, measuring leg muscle protein synthesis and expression of genes involved in myogenesis, inflammatory signaling and growth/atrophy in response to resistance exercise and whey protein supplementation in RA patients compared with that of control subjects. Each RA patient was carefully matched with a control subject based on age, gender, activity level and body mass index (BMI) to rule out direct effects of these parameters and focus on effects specifically related to the RA disease. The age and activity matching was important, since an impaired anabolic response - anabolic resistance - is reported with aging [23], and as even within the normal range of inflammatory indicators, both age and level of physical activity plays a role and could contribute to reductions in muscle mass with RA.

In a rat model of RA, adjuvant-induced arthritis, remarkable changes in skeletal muscle have been demonstrated [24–30], including increased mRNA expression of tumor necrosis factor (TNF-α), muscle ring-finger protein (MuRF1), atrogin1, insulin-like growth factor (IGF)-1, MyoD and myogenin in relation to muscle wasting and a reduced body weight gain during growth. Similar alterations in RA patients may underlie the muscle deterioration observed in these patients. However, whether expression of such anabolic or proteolytic pathway genes is altered in muscle of RA patients and how these are regulated by exercise and protein intake is to our knowledge currently unknown.

In recent years, treatment of RA patients has improved resulting in better quality of life for most patients. Therefore, we included well-treated RA patients receiving the anchor disease-modifying antirheumatic drug (DMARD), methotrexate, which is first-line medical treatment for RA patients. Patients receiving biological anti-TNF-α or steroid therapy were excluded, in order to obtain a homogenous experimental group, and due to the fact that glucocorticoids are expected to markedly affect skeletal muscle per se [31]. Although the level of systemic inflammation in RA is somewhat reduced during antirheumatic treatment, it has been shown not to lower the level completely down to that of healthy peers [32, 33], and we anticipated that the well-treated RA patients included in this study would still have increased levels of systemic inflammation [17, 32, 34–38].

This study reports for the first time an anabolic response of myofibrillar and collagen protein synthesis and gene expression to acute resistance exercise and protein feeding in RA patients, similar to that of healthy controls. However, expression of the genes coding for TNF-α, myogenin and hepatocyte growth factor (HGF)1 were more responsive in RA patients compared to controls.

**Methods**

**Subjects**

Thirteen patients diagnosed with RA according to the American College of Rheumatology (ACR) classification criteria from 1987 and not receiving anti-TNF-α or steroid therapy (6 months and 6 weeks washout, respectively) were included. All patients received methotrexate. Time since RA diagnosis ranged from 1 to 32 years (median 8 years). Exclusion criteria were: type 2 diabetes, BMI above 38, cardiovascular disease, cancer or known infections. Disease Activity Score in 28 joints (DAS28) range was 1.8–4.6 (mean 2.6, SD 1.0, n = 6), of these 50 % were seropositive. Each patient (RA) was carefully matched with a healthy control subject (CON) based on gender, age (+/− 2 yrs) and BMI (+/− 2 units). RA
patients were classified into one of four groups (1–4) of physical activity level according to the physical activity part of the Copenhagen City Heart Study questionnaire (Østerbrounderøsøgelsen, [39]). Matching CON subjects had to fit into the same activity group as the corresponding RA patient. For inclusion of matching controls 150 candidates were screened by telephone interviews. The study was approved by the Research Ethics Committees of the Capital Region of Denmark (H-4-2011-028) and conformed to the Declaration of Helsinki. All subjects gave written informed consent before participation. Subjects were asked to refrain from caffeine and alcohol for 1 and 3 days, respectively, prior to the experiment and to avoid exercise for the last 2 days before the experimental day.

**Pretest day**

Prior to the experimental day, subjects met for a pretest day for anthropometric measures, strength tests, dual-energy X-ray absorption (DXA) scanning, blood sampling, interview etc. Height was measured to the nearest centimeter and weight to the nearest 100 g, wearing light clothes and without shoes. Waist circumference was measured as the smallest circumference between anterior superior iliac spine and the lower ribs, and hip circumference as the largest circumference around the hips, both to the nearest centimeter. Body mass index (BMI) and waist/height ratio were calculated from these measurements. Following 10 min of supine rest, blood pressure and ‘resting’ heart rate were measured (Table 1a). Physical activity level of included subjects was recorded by use of the Physical Activity Scale (PAS) and converted to metabolic equivalent of task (MET) values as described by Aadahl and Jorgensen [40]. A brief dietary interview was performed to ensure that all included subjects consumed adequate protein and energy.

Body composition including lean body mass (LBM) was measured by a DXA scan (Model DPX-IQ, Lunar Corp., Madison, WI, USA) at medium speed (24 mSv). Appendicular lean soft tissue (ALST) was calculated as lean soft tissue in arms and legs [41]. Skeletal muscle index (SMI) was calculated as ALST/height$^2$ (H²). Furthermore fat-free mass/height$^2$ (FFM/H²) was calculated [42] (see Table 1b).

One repetition maximum (1 RM) was measured in a knee extension device (Technogym, Superexecutive Line, Gambottola, Italy) at range of motion 20°–100° (0° corresponds to full leg extension) and following individual adjustment and a brief warm-up consisting of low loads.

Maximal voluntary contraction (MVC) in isometric knee extension was determined for each leg at 70° of knee flexion using the Good Strength device (Version 3.14 Bluetooth; Metitur Ltd, Jyväskylä, Finland) after a 5-min warm-up on a stationary bike. The subjects were seated and fastened in a rigid chair with hips and knees flexed. A leg cuff, which was connected to a strain gauge through a

| Table 1 Baseline characteristics |
|----------------------------------|
| **A. Subject characteristics**   |
|                                  |
| **CON (n = 13)**                 |
| Mean    | SD   | RA (n = 13) | Mean | SD   | t test |
| Age (years) | 57  | 15  | 56  | 14  | 0.15   |
| Height (cm) | 169 | 5   | 167 | 4   | 0.32   |
| Body mass index (BMI) (kg/m$^2$) | 25  | 5   | 25  | 4   | 0.85   |
| Blood pressure (mmHg) | 134/81 | 18/8  | 134/80 | 19/10 | 0.94 |
| Waist/hip ratio | 0.88 | 0.08 | 0.92 | 0.06 | 0.07   |
| Resting heart rate (HR) (bpm) | 70  | 12  | 65  | 10  | 0.11   |
| **B. Body composition**          |
|                                  |
| **CON (n = 13)**                 |
| Mean    | SEM  | RA (n = 13) | Mean | SEM  | t test |
| Region % fat (fat %) | 31.0 | 2.9 | 31.3 | 3.0 | 0.90 |
| Lean body mass (LBM, kg) | 45.2 | 2.1 | 44.5 | 1.3 | 0.65 |
| Appendicular lean soft tissue (ALST, kg) | 19.5 | 1.1 | 19.0 | 0.6 | 0.60 |
| Skeletal muscle index (SMI, kg/m$^2$) | 6.8 | 0.3 | 6.8 | 0.2 | 0.54 |
| Fat-free mass/height$^2$ (FFM/H²) (kg/m$^2$) | 15.8 | 0.6 | 16.0 | 0.4 | 0.34 |
| **C. Strength and exercise**     |
|                                  |
| **CON (n = 13)**                 |
| Mean    | SEM  | n   | RA (n = 13) | Mean | SEM | n | t test |
| 1 repetition maximum (RM) exercised leg (kg) | 38.4 | 3.0 | 13 | 37.6 | 2.5 | 13 | 0.73 |
| Total kgs lifted | 252 | 23 | 13 | 262 | 16 | 13 | 0.62 |
| 1 RM right leg (kg) | 38.8 | 3.0 | 13 | 40.9 | 2.4 | 13 | 0.57 |
| Maximal voluntary contraction (MVC) right leg (Nm) | 176.1 | 10.2 | 11 | 179.9 | 16.6 | 8 | 0.71 |
| Physical activity | Physical Activity Scale (metabolic equivalent of tasks (METs)/24 hrs) | 44.4 | 1.7 | 13 | 39.5 | 1.2 | 13 | 0.026 |

CON control subjects, RA rheumatoid arthritis patients
rigid steel rod, was mounted on the leg just above the medial malleolus (Table 1c for strength data). Strength is expressed as moment in Nm, that is, corrected for lever arm length. The recorded moment was corrected for the effect of gravitational pull on the lower leg and foot by calibration before each measurement.

Resting blood samples were obtained by venipuncture for direct analysis of inflammatory cells and blood lipid profile at the Clinical Biochemistry Department, Bispebjerg Hospital, Copenhagen, using standard laboratory procedures. Furthermore, ethylenediaminetetraacetic acid (EDTA) plasma was stored at −80 °C pending analyses as described below.

Experimental protocol
On the experimental day, subjects arrived fasted in the morning by taxi to the Institute of Sports Medicine, Bispebjerg Hospital, Copenhagen, Denmark, where they were placed supine and remained rested. A catheter was inserted into an antecubital vein of each arm; one used for tracer infusion and one used for collection of blood samples throughout the study. The trial design and sampling protocol is shown in Fig. 1. After obtaining a background blood sample, the ring-$^{13}$C$_6$-phenylalanine tracer (sterile and pyrogen-free; Cambridge Isotopes Laboratories, Andover, MA, USA) was administered as a primed (8 umol/kg LBM), continuous (8 umol/kg LBM/hr) infusion. The tracer, which was mixed in sterile saline and sterilized through a 0.2-μm sterile disposable filter (Minisart, Sartorius Stedim Biotech GmbH, Goettingen, Germany), was infused throughout the experimental day (total infusion time 8 hrs). After 1½ hrs of tracer infusion, the first muscle biopsy was obtained from the resting leg (B; baseline). At 4 hrs the subjects moved to the exercise equipment and (after one set of warm-up knee extensions consisting of eight repetitions at 35 % of 1 RM) performed one-legged knee extension exercises consisting of ten sets of eight repetitions at 70 % of 1RM separated by a 1-min break where subjects remained seated in the knee-extensor device. Subjects were randomized to perform the exercise with their dominant or non-dominant leg. The exercise session was completed in approximately 30 min and was supervised by the experiment leader. The contralateral leg remained rested. Immediately after cessation of the exercise session (4½ hrs of tracer infusion) biopsies were obtained from both legs, at least 4 cm away from the previous biopsy. Immediately hereafter a protein drink consisting of 0.5 g intact whey protein isolate (Lacprodan-9224, Arla Foods Ingredients, Viby, Denmark)/kg LBM (12.5 % enriched with ring-$^{13}$C$_6$-phenylalanine) dissolved in 190 ml water was consumed (total amount in RA and CON groups: 25.3 (0.7) and 25.7 (1.2) g (mean (SEM)), respectively). Three hours later bilateral biopsies were obtained, at least 4 cm away from

![Fig. 1 Study design. The stable isotope labeled amino acid $^{13}$C$_6$-phenylalanine was infused throughout the study period, and fractional synthesis rate (FSR) of muscle protein (vastus lateralis) was measured in the resting, fasted (BASAL) state and after intake of whey protein alone (PROT) and in combination with unilateral resistance exercise (EX) (PROT + EX). Upper line of grey boxes represents one leg, lower line the contralateral leg. Muscle biopsy time points are marked with B](image)
any previous biopsies. The order of biopsies along one leg, and whether the exercised or rested leg was biopsied first was randomized among RA patients whereas identical procedures were followed in the matched CON subject.

**Blood samples and analyses**

Venous blood samples were drawn into EDTA tubes and cooled on ice for 10 min, followed by centrifugation (10 min at 3060 g at 4 °C), and the plasma phase was stored at −80 °C until analysis.

Plasma levels of the inflammatory markers C-reactive protein (CRP), interleukin (IL)-6 and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA) in blood samples obtained on the pretest day and the basal blood sample from the experimental day. The mean value of these is presented. ELISA kits (CRP DuoSet DY1707, IL-6 Quantikine H5 ELISA Kit HS600B and TNF-α HSTA00D) were from R&D Systems (Minneapolis, MN, USA) and procedures have been described previously [43]. Inflammatory cell profile and blood lipid profile (triglycerides, total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol) in basal blood samples was measured at the Clinical Biochemistry Department, Bispebjerg Hospital, Copenhagen, as previously described [43].

During the experimental day blood samples (see Fig. 1) were obtained at time points 0, 15, 90, 150, 210 and 270 min after commencement of isotope infusion and at time points +15, +30, +60, +90, +120 and +180 min after consumption of the protein drink, for determination of ring-$^{13}$C$_6$-phenylalanine enrichment and plasma glucose. Blood glucose was measured immediately using an Accu-Chek, Inform II (Roche Diagnostics, Basel, Switzerland).

**Muscle biopsies**

As shown in Fig. 1, a total of five biopsies (8) were obtained; baseline, rest, exercise (EX) 0, PROT 3 and PROT + EX 3 (at time points corresponding to 1½, 4½ and 7½ hrs of isotope infusion) providing three intervals for fractional protein synthesis rate (FSR) calculations; BASAL FSR (rest), PROT FSR (0–3 hrs after protein drink in rested leg), PROT + EX FSR (0–3 hrs after protein drink in exercised leg). The same five muscle biopsies were used for gene expression analyses by real-time reverse transcriptase polymerase chain reaction (RT-PCR) as described below. The muscle biopsies were obtained under local anesthetic (1 % lidocaine), through separate incisions at least 4 cm apart, in order to separate them as much as possible while still obtaining biopsies from reasonably similar areas of muscle, this has previously been shown not to affect FSR measurements [44]. The percutaneous needle biopsy technique with a 5-mm biopsy needle [45] and manual suction was used. The biopsy was freed from visible fat and connective tissue, and one piece immediately snap frozen (for later gene expression analyses) and another piece of approximately 30 mg (range 15.1–57.5) for stable isotope enrichments was wiped clean from blood in ice-cold saline, weighed, and snap frozen. Muscle biopsies were stored at −80 °C until analyses.

**Stable isotope analyses**

**Protein fractionation**

Raw skeletal muscle specimens were homogenized (Fast-prep, 120A-230; Thermo Savant, Holbrook, NY, USA) for 4 × 15 sec in 1 ml homogenization buffer (0.02 M Tris, pH 7.4, 0.15 M NaCl, 2 mM EDTA, 0.5 % Triton-X 100, 0.25 M sucrose) left overnight at 5 °C, then homogenized once again at day 2 and left at 4 °C for 1 hr before centrifugation (20 min, 1600 g, 4 °C). The supernatant was discarded and 1.5 mL of high-salt buffer (0.7 M KCl and 0.1 M pyrophosphate) was added to the pellet, which was vortexed for 30 sec and left at 4 °C overnight. After a spin (20 min, 1600 g, 4 °C), the supernatant (myofibrillar protein fraction) was transferred to new vials and the pellet (connective tissue fraction) washed once more with high-salt buffer and left for 2 hrs and centrifuged (20 min, 1600 g, 4 °C) again from which the supernatant was discarded. The myofibrillar proteins in the supernatant were precipitated by adding 3.45 mL ice-cold 99 % ethanol and left at 4 °C for 30 min. After spinning (20 min, 1600 g, 4 °C) the supernatant was discarded. Both myofibrillar and connective tissue protein pellets were added to 1 mL of 6 M HCl and left at 110 °C overnight to hydrolyze proteins. The analysis of protein-bound tracer abundances were carried out on the GC-C-IRMS equipment (Finnigan Delta Plus, Bremen, Germany) as described in more detail elsewhere [46].

**Precursor enrichment**

Free-skeletal amino acids were purified on resin columns (AG 50 W-X8 resin; Bio-Rad Laboratories, Hercules, CA, USA). After being washed, eluted and dried down under a stream of nitrogen, the purified amino acids were derivatized using N-methyl-N-(tert-butyldimethyilsilyl)trifluoroacetamide + 1 % tert-butyl-dimethylchlorosilane (Regis Technologies, Morton Grove, IL, USA) mixed 1:1 with acetonitrile. The MTBSTFA-derivative of phenylalanine was separated on a CP-Sil 8 CB capillary column (30 m, 0.32 mm ID; coating, 0.25 μm) (ChromPack; Varian, Palo Alto, CA, USA) and the isotope ratios were analyzed on a triple-stage quadrupole mass spectrometer (TSQ Quantum; Thermo Scientific, San Jose, CA, USA) operated in electron ionization mode. Chromatogram integration was carried out in MassRatio 2.72 (FB) Engineering, Frederiksværk, Denmark) and the tracer-to-tracee ratio (TTR) was calculated by subtracting the isotope ratio of a background sample from all the enriched samples.
Fractional synthesis rate calculations

The ring-\(^{13}\)C\(_6\)-phenylalanine enrichment of the myofibrillar and connective tissue muscle protein fractions measured by GC-C-IRMS (Hewlett Packard 5890-Finnegan gas chromatography-combustion III-Finnigan Delta\(^{\text{Plus}}\) isotope ratio mass spectrometry; Thermo Finnigan MAT, Bremen, Germany) were used to calculate the fractional synthesis rate (FSR) in percent per hour. Calculations are based on the incorporation rate of ring-\(^{13}\)C\(_6\)-phenylalanine into muscle proteins using a standard precursor–product model as follows:

\[
\text{FSR} (\%/hr) = \frac{\Delta E_{\text{product}} \times 100}{E_{\text{precursor}} \times \Delta t}
\]

where \(\Delta E_{\text{product}}\) is the change in tracer enrichment of protein-bound ring-\(^{13}\)C\(_6\)-phenylalanine in two biopsies from the same leg taken with a time interval of \(\Delta t\). Precursor is the mean precursor \(^{13}\)C\(_6\)-phenylalanine enrichment during that time interval. Here we used venous plasma tracer enrichments as a surrogate estimate of the precursor enrichment.

Whole-body rate of appearance (Ra) of \(^{13}\)C\(_6\)-phenylalanine (an estimate of whole-body protein breakdown rate) was calculated as:

\[
Ra = \frac{\text{Infusion rate}}{E_{\text{plateau}}}
\]

Where \(E_{\text{plateau}}\) was the weighted average of venous plasma enrichment throughout the basal or protein (PROT) + exercise (EX) periods or the two combined.

RNA extraction

RNA was extracted as described in [47]. Essentially, approximately 15 mg of frozen muscle tissue from each biopsy was homogenized in TRI Reagent (Molecular Research Center, Cincinnati, OH, USA), using 1-bromo-3-chloropropane for phase separation and isopropanol to precipitate RNA. The RNA pellet was washed in ethanol and dissolved in RNase-free water. RNA concentrations were determined by spectrophotometry at 260 nm. Quality of the RNA was checked by gel electrophoresis and spectrophotometer ratios at 260/240 nm (acceptable range 1.2–1.6 at pH 8) and 260/280 nm (1.8–2.0 at pH 7.5–8.0).

Real-time RT PCR analysis

Expression of a total of 26 different genes was measured (see Table 2 for full list) belonging to the following groups; satellite cell regulators and inflammation, heat shock proteins, myogenic regulatory factors, atrogenes and cytokines and their receptors.

Total RNA (500 ng from each muscle sample) was converted into cDNA in 20 ul using the OmniScript reverse transcriptase (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol.

For each target mRNA, 0.25 ul cDNA was amplified in a 25-ul SYBR Green PCR reaction containing 1 x Quantitect SYBR Green Master Mix (Qiagen) and 100 nM of each primer (Table 2). The amplification was monitored real time using the MX3005P real-time PCR machine (Stratagene, Santa Clara, CA, USA). The threshold cycle (Ct) values were related to standard curves made with PCR products to determine the relative difference between the unknown samples, accounting for the PCR efficiency. The specificity of the PCR products was confirmed by dissociation curve analysis after amplification. All mRNA data were normalized to ribosomal protein, large, P0 (RPLP0). For normalization control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), see Additional file 1. Baseline data (1.5 hrs rest, relative to mean CON) are shown in Additional file 2. mRNA expression data are presented as fold changes relative to individual baseline values.

Statistical analysis

Results are reported as mean (SE) unless otherwise stated. Protein synthesis and gene expression data were analyzed by two-way repeated-measures (RM) ANOVA (SigmaPlot 12.3, Systat Software Inc, San Jose, CA, USA) and Student-Newman-Keuls (SNK) post hoc test with correction for multiple comparisons. Significant effects of group (CON vs. RA) or biopsy and interaction (group x biopsy) are shown on graphs at a significance level of \(p < 0.05\). \(P\) values \(\leq 0.1\) are also shown on graphs, for trends. All mRNA data were log-transformed for statistical analyses and shown as geometric mean ± back-transformed SE. For some mRNA targets, the pattern of missing data led to exclusion of subject pairs from the statistical analyses, resulting in exclusion of the following number of subject pairs; IL1β = 4; IGF-1Ec = 1; IL1R = 1; cmet = 1. All other data (with only a single data point per subject) were compared by a paired two-tailed t test (Prism 6.02 for Windows, GraphPad Software Inc, La Jolla, CA, USA). Plasma ELISA data were log-transformed for statistical analyses.

Results and discussion

Baseline characteristics

As shown in Fig. 2, CRP was higher in the RA patients (2.25 (0.50) mg/l) than in CON subjects (1.07 (0.25) mg/l; \(p = 0.038\)), TNF-α was higher in RA (1.18 (0.30) pg/ml) than CON (0.64 (0.07) pg/ml; \(p = 0.008\)) and IL-6 tended to be higher in RA (RA 2.89 (0.68) pg/ml; CON 1.74 (0.32) pg/ml; \(p = 0.065\)). Although going in the same direction, these differences in inflammatory markers between RA patients and healthy CON individuals were not as pronounced as previously reported in a majority of studies.
Table 2  Primers used for real-time RT-PCR

| Target  | Sense primer                                   | Antisense primer                                   |
|---------|-----------------------------------------------|----------------------------------------------------|
| RPLP0   | GGAAACTCTGCATTCTCCTGTCTTCT                  | CCAGGACTCTGGTTGACCCGCTTCT                          |
| GAPDH   | CACTTCGCCACCCACCAACTGCTT                   | GAGGGGCTACCCAGCTACTTCT                             |
| IGF-Ie  | GACATCAGCAGCAGCCACACAGGAGA                  | CGGTGAGCTGACTGACTACCT                              |
| IGF-Ic  | GCCCCCATCTACCAACAAAGAACAC                  | CGGTGAGCTGACTGACTACCT                              |
| HGF     | TGAAATATGCGCTGGGGCTGTTGAA                  | ACAACCAAGGCTGACCCACTATCAC                          |
| Cmet    | AAACCCGAATCTCGCCGCCACC                   | TGGATTTGTTGTCCACATCTC                              |
| MCP1    | GCCCTTCTGTCATGGTCTGTGTC                  | GCAAGGCTATGGGCTGACACC                             |
| COX1    | GTCATTGGGAAATTCCACCTCCATT                  | CTTCCACTCTGCTGACACTT                              |
| COX2    | TGGAACTACAGTTACCCATTTTCGTTG                 | TGGTATCTTTGCTGACACTT                              |
| HSP70   | GTGGCATGAGCACCAAACCTT                   | TATTTTACTGCTGACACTT                               |
| HSP27   | GCTGACGTAGAAGCAGAGAAC                      | TGAACCACCGGAGAGAAGGCCC                            |
| αB-crystallin | GTGGGAGATGAGTTGAATGGTGA   | CTTGAGGCTCAGGACCAGC                               |
| Myogenin | CTGACATCAGATGGGCTGACAG                  | GATGGGCTACACAGACGACCA                              |
| Myf6    | GGGCTGACAGGCTAGCTACCTTC                   | TGGTATCTTTGCTGACACTT                              |
| MyoD    | AGAAGGGCTGCTCAGCAAGC                      | TGGTATCTTTGCTGACACTT                              |
| Myostatin | GTGGCATGAGCACCAAACCTT                 | TGTCCACAGTGGAAAGGCA                                |
| Atrogin1 | TGGGACTGAGGTCTGACGACAG                   | TGGTATCTTTGCTGACACTT                              |
| MuRF1   | GGAGGCTGAGTTGGAAGAAGGAGTAGTATGGGA        | ACGGAGAGCTCGCTGAGTAGTATGG                         |
| TNFa    | TGGGAGGAGTTGGAAGAAGGAGTAGTATGGGA        | ACGGAGAGCTCGCTGAGTAGTATGG                         |
| TNFRI   | CCGCAGGAGTTGGAAGAAGGAGTAGTATGGGA        | ACGGAGAGCTCGCTGAGTAGTATGG                         |
| TNFRII  | CCGCAGGAGTTGGAAGAAGGAGTAGTATGGGA       | ACGGAGAGCTCGCTGAGTAGTATGG                         |
| IL-1β   | TTGGGAGGAGTTGGAAGAAGGAGTAGTATGGGA      | ACGGAGAGCTCGCTGAGTAGTATGG                         |
| IL-6    | GGAGGCTGAGTTGGAAGAAGGAGTAGTATGGGA      | ACGGAGAGCTCGCTGAGTAGTATGG                         |
| IL-6R   | CCAGGAGGAGTTGGAAGAAGGAGTAGTATGGGA     | ACGGAGAGCTCGCTGAGTAGTATGG                         |

Abbreviations: RT-PCR real-time reverse transcriptase-polymerase chain reaction, RPLP0 large ribosomal protein P0, GAPDH glyceraldehyde-3-phosphate dehydrogenase, IGF insulin-like growth factor, HGF hepatocyte growth factor, MCP1 monocyte chemoattractant protein = CCL2, COX cyclooxygenase, HSP heat shock protein, MuRF1 muscle ring finger protein 1, TNF tumor necrosis factor, IL interleukin, R receptor

The HGF primers are specific for the two largest splice variants including the SP domain

Fig. 2  Systemic inflammatory markers. Plasma levels of the inflammatory markers tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and C-reactive protein (CRP) measured in controls (CON) and RA patients (RA). Individual data (mean of two sampling days) were log-transformed for statistical analyses and data are shown on log scales with line at geometric means. Significance level of paired comparisons is given on graphs.
[32, 35, 37, 38, 48, 49], but were similar to the moderate levels observed by Crowson et al. [50]. Most likely, the limited elevation of systemic inflammatory markers emphasizes the very well-functioning state of the RA patients participating in this study.

The overview of subject characteristics in Table 1 reveals many similarities between RA and CON groups. However, waist/hip ratio (Table 1a) tended to be higher in RA than CON (p = 0.07). Among RA patients, six were smokers (5–20 cigarettes/day, mean 10) and among controls four were smokers (1–17 cigarettes/day, mean 10). Use of medication in the two groups is shown in Table 3. These records show that all RA patients use medication of some type, mostly DMARDs like methotrexate (all 13 patients) and salazopyrin (5/13 patients). Pain relief medication was frequently used by RA patients, mostly paracetamol (7/13 patients) and nonsteroidal anti-inflammatory drugs (NSAIDs) (3/13) whereas only a single CON participant reported use of each of these drugs. Most RA patients had some comorbidity (see Additional file 3 for complete list), except for two patients. No subjects from the CON group used any rheumatic drugs and had only a minor intake of painkillers. Seven CON subjects were completely free from comorbidities. These differences in comorbidities and medication could be confounding the systemic inflammation data (Fig. 2), since some comorbidities may contribute to an elevation of inflammatory markers while antirheumatic medication is likely to reduce these markers. Body composition measures (Table 1b) were not different between RA and CON, likewise, no differences in knee extensor muscle strength (Table 1c) measured as one repetition maximum (1 RM) and maximal voluntary contraction (MVC) were observed between groups. The total number of kg lifted during the experimental acute exercise session was not different between groups (Table 1c). When estimated by PAS, physical activity level turned out higher in CON than in RA (p = 0.026). The similarities in body composition between RA patients and CON were somewhat surprising and in contrast to previous reports of reduced muscle mass [2, 16, 42] and increased fat accumulation in RA patients [51, 52]. Furthermore, the similar muscle strength between RA and CON indicate that the patients were well-functioning in comparison to those participating in previous studies [16, 17, 38, 53, 54]. Data on blood lipid profile and circulating inflammatory cells is given in Table 4. Although metabolic changes are usually reported at all stages of RA disease [19], we detected neither differences between RA and CON in blood lipid profile, blood pressure, metabolic syndrome biomarkers, fasting glucose, nor in the circulating inflammatory cell profile for all of which changes have previously been reported in RA patients [19, 48, 50]. Again, this reflects the clinically well-controlled condition of the participating patients. Throughout the experimental day, blood glucose level was not different between groups and was stable around 5 mmol/l (Fig. 3 and Table 4b).

### Muscle protein synthesis

Fractional synthesis rate (FSR) of muscle myofibrillar and connective tissue protein is shown in Fig. 4. The myofibrillar protein synthesis was enhanced in response to protein intake (p < 0.05) and was further increased when combined with heavy resistance exercise (p < 0.001). This response was similar in CON and RA groups. Connective tissue protein synthesis was increased after exercise combined with protein intake (p < 0.001), but not by protein intake alone (p > 0.1). Irrespective of state (fasting, protein fed alone or in combination with exercise), connective tissue FSR tended to be higher in RA than CON (p = 0.060). Plasma tracer enrichment (Fig. 5) was lower

---

### Table 3 Medication

| Medication               | CON | RA |
|-------------------------|-----|----|
| Methotrexate            | 0   | 13 |
| Salazopyrin             | 0   | 5  |
| Paracetamol             | 1   | 7  |
| NSAID                   | 1   | 3  |
| Acetylsalicylic acid    | 2   | 0  |
| Anti-asthmatics         | 0   | 4  |
| Folic acid              | 0   | 8  |
| Statins                 | 1   | 1  |
| ACE inhibitors          | 0   | 3  |
| Hormone therapy         | 0   | 1  |
| Pain relief (tramadol)  | 0   | 1  |
| No medication           | 9   | 0  |

Abbreviations: CON control subjects, RA rheumatoid arthritis patients, NSAID nonsteroidal anti-inflammatory drug, ACE angiotensin-converting enzyme

### Table 4 Inflammatory cells & Blood lipid profile

|                     | CON (n = 13) | RA (n = 13) |
|---------------------|-------------|-------------|
|                     | Mean | SEM | Mean | SEM | t test |
| A. Inflammatory cell profile |      |      |      |      |       |
| Leucocytes (x10⁹/l)  | 7.3  | 0.4 | 6.7  | 0.7 | 0.53  |
| Neutrophils (x10⁹/l)| 4.7  | 0.3 | 4.1  | 0.6 | 0.44  |
| Lymphocytes (x10⁹/l)| 1.81 | 0.13| 1.82 | 0.19| 0.96  |
| Monocytes (x10⁹/l)  | 0.57 | 0.05| 0.55 | 0.05| 0.77  |
| B. Blood lipid profile |      |      |      |      |       |
| Triglycerides (mmol/l)| 1.2 | 0.1 | 1.4  | 0.2 | 0.41  |
| Total cholesterol (mmol/l) | 5.3 | 0.3 | 5.5  | 0.3 | 0.75  |
| HDL cholesterol (mmol/l)| 1.7 | 0.1 | 1.6  | 0.1 | 0.44  |
| LDL cholesterol (mmol/l)| 3.1 | 0.2 | 3.4  | 0.3 | 0.28  |
| Fasting glucose (mmol/l)| 5.0 | 0.2 | 5.3  | 0.2 | 0.66  |

Abbreviations: CON control subjects, RA rheumatoid arthritis patients, HDL, high-density lipoprotein, LDL, low-density lipoprotein
in RA vs. CON throughout the infusion period \( (p = 0.028) \) (ranged between 0.11 and 0.14 in RA and 0.12 and 0.18 in CON). Whole-body protein breakdown rate (rate of tracer amino acid appearance) was reduced following protein intake (PROT) and one-legged resistance exercise (EX) \( (\text{BASAL} = 64.4 \text{ (SE } 3.8) \text{ and } 71.5 \text{ (SE } 3.2) \text{ and PROT + EX} = 58.5 \text{ (SE } 2.4) \text{ and } 63.6 \text{ (SE } 2.1) \text{ } \mu \text{mol/kg LBM/hr in CON and RA, respectively; time } p < 0.001) \) and tended to be higher in RA than in CON as an average over the entire study period \( (\text{TOTAL; } p = 0.11) \). However, the whole-body assessment of protein turnover is neither protein nor tissue specific and we cannot say whether the tendency to a higher protein turnover rate in RA patients is a general phenomenon or may be related to a specific tissue (i.e., skeletal muscle) or protein type.

We showed a comparable basal muscle protein synthesis rate in RA and CON \( (\text{Fig. 4a and b). Muscle protein turnover in patients with RA has to our knowledge been investigated in only one human study previously [55], showing that the resting, fastest FSR in RA patients not receiving steroid therapy was similar to osteoarthritis patients serving as controls. Further, the present study shows for the first time an anabolic response (elevated myofibrillar FSR) to acute whey protein feeding alone, which was amplified when combined with acute resistance exercise in patients with RA. Additionally, this response was not different from that observed in healthy control subjects matched for age, gender, BMI and physical activity. Apparently, in our RA patients the connective tissue fraction was less responsive to nutritional intervention than the myofibrillar fraction, which is in accordance with previous findings [56]. For further details of the anabolic response to acute exercise and protein feeding, protein expression and signaling analyses of targets of the Akt-mTOR signaling pathway would have been relevant, however, since we observed similar FSR responses in RA and CON, we chose to focus on transcriptional regulation of genes involved in other aspects of muscle adaptation as described in the following section.

**Muscle gene expression**

In the present study, expression of genes related to inflammatory signaling, myogenesis and muscle growth/atrophy as well as heat shock proteins responded similarly in RA and CON. No differences were observed in basal gene expression level between RA and CON \( (\text{Additional file } 2) \). Changes in mRNA expression from baseline is shown in Figs. 6, 7, 8, 9 and 10, divided into subgroups related to satellite cell (SC) regulators and inflammation \( (\text{Fig. 6}), \text{heat shock proteins (Fig. 7}), \text{myogenic regulatory factors (Fig. 8}), \text{atrogenes (Fig. 9), as well as cytokines and receptors (Fig. 10). As shown in Fig. 6, HGF1 expression was overall higher in RA vs. CON (Group, } p = 0.026\text{, specifically HGF1 expression was higher in RA patients than CON at EX0 and PROT + EX3 (} p < 0.001 \text{ and } p = 0.004, \text{ respectively). The higher expression of HGF1 in RA than CON indicate an increased sensitivity toward signaling via this pathway in RA patients, which could be located to the skeletal muscle stem cells, SCs, since HGF1 signaling is involved in activation of SC [57, 58], although our gene expression analysis is not specific to the SCs. HGF1 activates SCs via binding to the cmet receptor [59]. However, no significant changes in gene expression of the HGF1 receptor, cmet, were observed, indicating that this is not the regulatory site for this pathway. Macrophage chemoattractant protein 1 (MCP-1, also known as}

![Blood glucose levels](image)
CCL2) was induced by exercise (but not protein feeding), both acutely (EX 0, \( p = 0.02 \)) and even more 3 hrs later (\( p < 0.001 \)) in both groups combined. This indicates that it is involved in the adaptive response to resistance exercise. Potentially, it plays a role in crosstalk between inflammatory cells (macrophages) and SC, as indicated by its colocalization with these cells [60]. Cyclooxygenase 2 (COX2) expression was induced immediately after exercise (\( p = 0.011 \)), in line with previous reports [61, 62], although at later time points. In contrast, we and others have previously reported COX2 induction only when exercise was combined with COX inhibition [47, 63]. Taken

Fig. 4 Fractional synthesis rate (FSR) of muscle myofibrillar and connective tissue protein. FSR of muscle myofibrillar (a) and connective tissue (b) protein given in %/hr in control (CON) and rheumatoid arthritis (RA) patient groups, measured in the resting, fasted (BASAL) state and after intake of whey protein alone (PROT) and in combination with unilateral resistance exercise (EX) (PROT + EX). Black bars denote rheumatoid arthritis patients (RA, n = 13) and grey bars healthy controls (CON, n = 12–13). Letters \( a \), \( b \) and \( c \) denote significant differences between sampling time points (two-way RM ANOVA)
together, we observed some indications on involvement of HGF1, MCP-1 and COX2 in the adaptive response to exercise, however, differential regulation between RA and CON was only observed for HGF1.

In Fig. 7 mRNA expression of heat shock proteins (HSPs) is shown. All three HSPs (HSP70, HSP27 and αB-crystallin) were induced by exercise both immediately after (EX 0, \( p < 0.001 \)) and 3 hrs later (PROT + EX 3, \( p < 0.001 \)), but not by protein intake. The induction of HSPs a few minutes after exercise (EX0), suggests that the HSP response to unaccustomed exercise is even more acute than previously shown (as discussed in [64]) and that muscle of RA patients is equally responsive as in CON.

Myogenic regulatory factors (Fig. 8) were induced by exercise combined with protein intake but not by protein intake alone. Myogenin expression was higher in RA than CON (Group; \( p = 0.021 \)), pointing at an increased responsiveness in RA patients, although this was not apparent for the other myogenic regulatory factors Myf6 and MyoD. Myf6 expression was increased both immediately after exercise (EX 0, \( p < 0.001 \)) and 3 hrs later (PROT + EX 3, \( p < 0.001 \)). Expression of MyoD was increased only 3 hrs after exercise (PROT + EX 3, \( p < 0.001 \)). In general, myogenic regulatory factors were induced by exercise, and mainly after 3 hrs compared with immediately after, which is in line with previous observations.
and the response was not different between RA and CON. Nor did we observe a difference in resting gene expression between RA and CON (Additional file 2) in the current study. In muscle from a rat model of RA (adjuvant-induced arthritis) both protein and mRNA expression of MyoD and myogenin were increased at rest, however, this was not investigated in relation to exercise [24–26].

Expression of myostatin and the atrogenes Atrogin1 and MuRF1 is shown in Fig. 9. The negative regulator of

Fig. 6 Satellite cell regulators and inflammation. mRNA expression relative to 1.5 hrs (baseline). For hepatocyte growth factor 1 (HGF1), letters a-b denote significant differences within controls (CON)
muscle mass, myostatin, was downregulated 3 hrs after exercise + protein (PROT + EX 3, \( p < 0.001 \)) and responds to exercise in an overall similar manner in RA patients and CON. Atrogin1 was downregulated 3 hrs after protein intake alone (PROT 3, \( p < 0.001 \)) and in combination with exercise (PROT + EX 3, \( p < 0.001 \)), whereas MuRF1 was downregulated 3 hrs after protein intake alone (PROT 3, \( p < 0.001 \)), but upregulated 3 hrs after exercise combined with protein intake (PROT + EX 3, \( p < 0.001 \)). Also for the atrogenes, no impact of RA could be observed. In muscle of the rat model of RA, mRNA expression of MuRF1 and atrogin1 was markedly increased [27, 29, 30], however, this difference was not apparent in our human subjects. Similarly, COX2 expression was markedly increased in muscle of arthritic rats, which was not reproduced in the RA patients of the present study either (Fig. 6).

Figure 10 displays mRNA expression of selected cytokines and their receptors. TNF-\( \alpha \) expression was higher in RA than in CON across all biopsy points (Group, \( p = 0.036 \)) and was induced immediately after exercise (EX 0, \( p < 0.001 \)); the former is in line with the increased mRNA expression of TNF-\( \alpha \) found in gastrocnemius muscle of rats with adjuvant-induced arthritis [27, 29] indicating a more responsive TNF-\( \alpha \) expression in muscle from RA patients. TNF-\( \alpha \) is believed to be a central mediator of muscle wasting in rheumatoid arthritis by alteration of the balance between muscle protein synthesis and breakdown. Via inhibition of signaling from the insulin receptor [67] and IGF-1 receptor via JNK and IRS-1 [68], TNF-\( \alpha \) can reduce peripheral insulin action and interfere with IGF-1 signaling, leading to a reduction of the anabolic responsiveness. Anti-TNF-\( \alpha \) therapies have proven effective in RA although muscle mass is not necessarily reversed by anti-TNF-\( \alpha \) treatment [32]. However, the anabolic response to a positive energy balance was improved by anti-TNF-\( \alpha \) treatment, seen by a larger gain of fat-free mass compared with methotrexate treatment [35] and supporting a role for TNF-\( \alpha \) in the regulation of muscle mass. Interestingly, the higher TNF-\( \alpha \) expression in the present study did not result in such differences in muscle mass or acute anabolic response, leaving the significance of this differential TNF-\( \alpha \) expression an open question.
TNFR1 expression was slightly increased 3 hrs after protein + exercise (PROT + EX 3, \( p < 0.001 \)), whereas no changes were observed for TNFR2 or IL-1\( \beta \). Induction of TNFR expression 3 hrs after exercise + protein has to our knowledge not been reported before, although higher levels of TNFR1 gene expression was recently reported in older (61 and 76 years) compared to younger subjects (40 years) [69], both at rest and 24 hrs after acute resistance exercise. Generally, regulation of TNF receptors in human muscle is not well understood. Both TNFR1 and 2 were expressed at high levels in the present study, while correlations were observed between TNFR1 and 2 expression (\( r = 0.57, p = 0.003 \), data not shown). Inflammatory signaling via IL-6, IL-6R and IL-1R was induced by exercise with an early upregulation of IL-6 immediately after exercise (EX 0, \( p < 0.001 \)) and to a lesser extent in the resting leg (REST, \( p < 0.001 \)) whereas the receptors were upregulated 3 hrs after exercise + protein (PROT + EX 3, \( p < 0.001 \)). None of these responses were different between RA and CON, indicating a normal cytokine response to acute resistance exercise in RA patients.

At baseline no differences in mRNA expression between RA and CON were observed for any of the investigated target genes (Additional file 2), although in skeletal muscle of arthritic rats, marked changes in gene expression induced by the disease have been consistently reported.

Thus, our human data from RA patients do not confirm the upregulation of muscle regulatory, inflammatory and catabolic markers found in animal models of RA, which is in line with the overall healthy state and preserved anabolic response of RA patients in the present study.

In contrast to the present findings in RA patients, remarkable differences in gene expression between elderly and young muscle previously have been reported including an elevated expression of inflammatory genes [69, 70], atrogenes [71] and MRFs [65] in resting skeletal muscle. Within the same time frame as used in the present study, Atrogin1 is induced by exercise only in old muscle [71], and IL-6 induction and myostatin downregulation by resistance exercise are more pronounced in old compared to young muscle [70, 72]. Together these results from elderly muscle indicate increased muscle inflammation susceptibility [69] and an altered acute muscle adaptive
response to exercise in elderly muscle, which could also contribute to the muscle deficits in RA patients. However, apart from a more pronounced induction of TNF-α, HGF1 and myogenin in RA vs. CON, this was not the case in the present study. Previously, knowledge about regulation of muscle gene expression in RA has relied only on animal studies, but from the current study we can now add human data.

Taken together, our gene expression data indicate that specific targets involved in muscle and SC regulation (HGF1, myogenin and TNF-α) are induced to a larger extent in RA patients than in healthy CON subjects, however, the majority of genes investigated showed similar responses in RA vs. CON indicating that skeletal muscle tissue of RA patients responds equally well to an acute exercise stimulus compared to healthy CON subjects.

**Limitations**
Keeping in mind that results may not apply for RA patients in general, the present study indicate that skeletal muscle of RA patients does not differ markedly from healthy control muscle and that they respond to protein intake alone and in combination with exercise in a similar way. The patients participating in the present study were a selected group of well-functioning RA patients, and thus no changes in either muscle strength or muscle mass were detected, which reduces the external validity of the study and leaves the question open of how RA patients with highly elevated systemic inflammatory levels and/or cachexia are characterized with respect to molecular (signaling) regulators of muscle mass and muscle protein turnover in response to the same interventions.

**Conclusions**
In conclusion, muscle protein synthesis and transcriptional regulation can be stimulated with both protein intake and physical exercise in patients with RA to a similar degree as in healthy individuals. These findings show that characteristics inherent of RA disease do not affect the muscle protein synthesis and gene expression response to acute exercise and protein intake, when factors like BMI, age and activity level are controlled by carefully matching each patient with a corresponding healthy control subject.
Fig. 10 Cytokines and receptors. mRNA expression relative to 1.5 hrs (baseline). Tumor necrosis factor receptor 1 (TNFR1) and interleukin (IL)-6 expression at REST was significantly different from baseline.
**Additional files**

**Additional file 1: Normalization control.** GAPDH gene expression data normalized to RPLP0 and individual baseline values, log-transformed for statistical analyses and shown on a logarithmic scale as geometric mean ± SEM. Black bars denote rheumatoid arthritis patients (RA, n = 13) and grey bars healthy controls (CON, n = 13). (PDF 173 kb)

**Additional file 2: mRNA expression at baseline.** Baseline expression of all targets is expressed relative to mean healthy CON at baseline. Gene expression data were normalized to RPLP0, log-transformed for statistical analyses and shown on a logarithmic scale as geometric mean ± SEM. Black bars denote rheumatoid arthritis patients (RA, n = 13) and grey bars healthy controls (CON, n = 13). No significant differences were observed between groups. (PDF 177 kb)

**Additional file 3: Comorbidities.** Table of reported comorbidities in rheumatoid arthritis patients (RA) and healthy controls (CON). The number of subjects reporting each comorbidity is given. (PDF 179 kb)

Abbreviations

AOR: American College of Rheumatology; ALST: appendicular lean soft tissue; B: baseline; BMI: body mass index; CON: control; COPD: chronic obstructive pulmonary disease; COX: cyclooxygenase; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; DMARD: disease-modifying antirheumatic drug; DXA: dual-energy X-ray absorption; E: enrichment; EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; EX: exercise; FFMI: fat-free mass; FSR: fractional synthesis rate; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; H: height; HDL: high-density lipoprotein; HGF: hepatocyte growth factor; HSP: heat shock protein; IGFBP: insulin-like growth factor; IL: interleukin; LBM: lean body mass; LDL: low-density lipoprotein; MCRP: monocyte chemoattractant protein = CCL2; MET: metabolic equivalent of task; MuRF1: muscle ring finger protein 1; MVC: maximal voluntary contraction; NSAID: nonsteroidal anti-inflammatory drug; PAS: Physical Activity Scale; PCR: polymerase chain reaction; SCs: satellite cells; SMI: skeletal muscle index; TNF: tumor necrosis factor; TR: tracer-to-tracer ratio.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

URM conceived of the study, participated in its design, carried out the study, data acquisition, data analyses and interpretation, and wrote the manuscript. KD participated in the design of the study, acquisition and interpretation of data, and revised the manuscript. MBA participated in the recruitment of subjects, execution of the study and acquisition of data. AB and NNMCI participated in execution of the study and acquisition of data, and revised the manuscript. UJS participated in subject recruitment, coordination of the study and interpretation of data, and revised the manuscript. PS performed gene expression analyses and analysis and interpretation of data, and wrote the manuscript. MK participated in the conception of the study, interpretation of data, and wrote the manuscript. LH participated in the design of the study, performed stable isotope analyses and interpretation of data, and wrote the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgements

Camilla Brink Sørensen, Ann-Marie Sedstrøm, Ida Trondhjem Haakkanson and Ann-Christina Reimann are thanked for their expert technical assistance. Funding is greatly acknowledged from The Danish Medical Research Council (10-094021), Nordea Healthy Aging, The Danish Rheumatism Association (R93-A1669), and Arla Foods Ingredients who provided the Lacprodan whey protein.

Author details

1 Institute of Sports Medicine, Department of Orthopaedic Surgery, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Bispebjerg Hospital bldg 8, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark. 2 Section for Sports Science, Institute of Public Health, Aarhus University, Dalgas Avenue 4, 8000 Aarhus C, Denmark. 3 Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57, 2600 Glostrup, Denmark. 4 Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.

Received: 21 January 2015 Accepted: 17 August 2015 Published online: 25 September 2015

References

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis G. Guidelines for the management of rheumatoid arthritis 2002 Update. Arthritis Rheum. 2002;46:328–46.
2. Summers GD, Deighton CM, Rennie MJ, Booth AH. Rheumatoid cachexia: a clinical perspective. Rheumatology. 2008;47:1124–31.
3. Roubenoff R. Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century. Arthritis Res Ther. 2009;11:108.
4. Reu I, Magne H, Savary-Auzeloux I, Averous J, Bos C, Peyron MA, et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J Physiol. 2009;587:5483–92.
5. Balage M, Averous J, Remond D, Bos C, Pujo-Guilcot E, Patel I, et al. Presence of low-grade inflammation impaired postprandial stimulation of muscle protein synthesis in old rats. J Nutr Biochem. 2010;21:325–31.
6. van Hees HW, Schellekens WJ, Linksels M, Leenders F, Zoli I, Donders R, et al. Plasma from septic shock patients induces loss of muscle protein. Crit Care. 2011;15:R233.
7. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest. 2013;123:4821–35.
8. Op den Kamp CM, Langen RC, Snepvangers FJ, de Theije CC, Schellekens JM, Laufs F, et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013;98:378–88.
9. Degens H, Ailaw SE. Control of muscle size during disease, disease, and aging. Int J Sports Med. 2006;27:94–9.
10. Petersen JM, Bakkar N, Guttridge DC. NF-kappaB signaling in skeletal muscle health and disease. Curr Top Dev Biol. 2011;96:85–119.
11. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Moel Mech. 2013;6:23–39.
12. Marquis K, Debiirge R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Mid-thigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:809–13.
13. Prado OM, Lieffers JR, McMargar LR, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2006;7:29–35.
14. Langen RC, Gokser HR, Remels AH, Schols AM. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2013;45:2245–56.
15. D’Souza DM, Al-Sajee D, Hawke TJ. Diabetic myopathy: impact of diabetes mellitus on skeletal muscle progenitor cells. Front Physiol. 2013;4:379.
16. Baker JF, Von Feldt J, Mostoufi-Moab S, Noaiseh G, Taratuta E, Kim W, et al. Deficits in muscle mass, muscle density, and modified associations with fat in rheumatoid arthritis. Arthritis Care Res. 2014;66:1612–8.
17. Beenakker KG, Ling CH, Meskers CG, de Craen AJ, Stijnen T, Westendorp RG, et al. Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Res Rev. 2010;9:431–6.
18. Stenstrom CH, Minor MA. Evidence for the benefit of aerobic and strengthening exercise in rheumatoid arthritis. Arthritis Rheum. 2003;49:28–34.
19. Kerekes G, Nurmonhamed MT, Gonzalez-Gay MA, Seres I, Parad G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10:691–6.
20. Ferraz-Amaro I, Gonzalez-Juanatey C, Lopez-Mejias R, Riancho-Zarrabeitia L, Gonzalez-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm. 2013;2013:710928.
21. Ferraz-Amaro I, Garcia-Dopico JA, Medina-Vega L, Gonzalez-Gay MA, Diaz-Gonzalez F. Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients. Arthritis Res Ther. 2013;15:R17.

22. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26:535–61.

23. Burd NA, Gottdenker SH, van Loon LJ. Arabinose resistance of muscle protein synthesis with aging. Exerc. Sport Sci. Rev. 2011;39:169–73.

24. Castellero E, Martin AI, Lopez-Menduina M, Granado M, Villanua MA, Lopez-Calderon A. IGF-1 system, atrogens and myogenic regulatory factors in arthritis induced muscle wasting. Mol Cell Endocrinol. 2009;3098–16.

25. Castellero E, Martin AI, Lopez-Menduina M, Villanua MA, Lopez-Calderon A. Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogen-1 and on myogenic regulatory factors. Am J Physiol Regul Integr Comp Physiol. 2009;297:E132–33.

26. Castellero E, Nieto-Bona MP, Fernandez-Galaz C, Martin AI, Lopez-Menduina M, Granado M, et al. Fenofibrate, a PPARalpha agonist, decreases atrogens and myostatin expression and inhibits arthritis-induced skeletal muscle atrophy. Arzneimittelforschung Metab. 2011;60:E90–9.

27. Granado M, Martin AI, Priego T, Lopez-Calderon A, Villanua MA. Tumour necrosis factor blockade did not prevent the increase of muscular muscle RNG finger-1 and muscle atrophy lF-3 box in arthritic rats. J Endocrinol. 2006:191:319–26.

28. Granado M, Priego T, Martin AI, Vara E, Lopez-Calderon A, Angeles VM. Anti-tumor necrosis factor agent PEG-sTNFRI improves the growth hormone/insulin-like growth factor-1 system in adjuvant-induced arthritic rats. Eur J Pharmacol. 2006;562:204–10.

29. Granado M, Martin AI, Villanua MA, Lopez-Calderon A. Experimental arthritis inhibits the insulin-like growth factor-1 axis and induces muscle wasting through cyclooxygenase-2 activation. Am J Physiol Endocrinol Metab. 2007;292:E1655–66.

30. Lopez-Menduina M, Martin AI, Castellero E, Villanua MA, Lopez-Calderon A. Systemic GF-1 administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius muscle atrophy and decreases atoger-1 and IGFBP-3. Am J Physiol Regul Integr Comp Physiol. 2010;299:R541–51.

31. Schakman O, Kalista S, Barbe C, Loumaye A, Thissen JP. Glucocorticoid-induced muscle atrophy. Int J Biochem Cell Biol. 2013;45:2163–72.

32. Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology. 2007;46:1924–7.

33. Hetland ML, Jensen DV, Knob GS. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. Clin Exp Rheumatol. 2014:32:141–6.

34. Rall LC, Rosen CJ, Dolnikowski G, Hartman WD, Lundgren N, Abad LW, et al. Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Arthritis Rheum. 1994;38:1115–24.

35. Marcorsa MA, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84:1463–72.

36. Valle Y, Ledema-Lozano IY, Torres-Carrillo N, Padilla-Gutierrez JR, Navarro-Hernandez RE, Vazquez-Del Mercado M, et al. Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis. Scand J Rheumatol. 2009;38:332–5.

37. Metsios GS, Stavropoulos-Kalinoglou A, Trehane GL, Nevill AM, Sandoo A, Panoulas VF, et al. Disease activity and low physical activity associated with number of hospital admissions and length of hospitalisation in patients with rheumatoid arthritis. Arthritis Res Ther. 2011;13:R108.

38. Biranne LM, Scott DL, Hurley MW. Exercise can reverse quadriceps senosimotor dysfunction that is associated with rheumatoid arthritis without exacerbating disease activity. Rheumatology. 2002;41:157–66.

39. Østbørnebroeselgen http://www.si-folkesundhet.dk/upload/ 6 asterborendereselgen.pdf.

40. Aadal M, Jorgensen T. Validation of a new self-report instrument for measuring physical activity. Med Sci Sports Exerc. 2003;35:1196–202.

41. Kim JW, Yang J, McDaniel SI, Baumgartner RN, Gallagger D. Total-body skeletal muscle mass estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr. 2002;67:378–83.

42. Arshad A, Rashid R, Benjamin K. The effect of disease activity on fat-free mass and resting energy expenditure in patients with rheumatoid arthritis versus noninflammatory arthropathies/soft tissue rheumatism. Modern Rheumatol. 2007;17:470–5.
66. Drummond MJ, Miyazaki M, Dreyer HC, Pennings B, Dhanani S, Volpi E, et al. Expression of growth-related genes in young and older human skeletal muscle following an acute stimulation of protein synthesis. J Appl Physiol. 2009;106:1403–11.

67. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994;91:4854–8.

68. Grounds MD, Radley HG, Ganski BL, Bogoyevitch MA, Shavlakadze T. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Clin Exp Pharmacol Physiol. 2008;35:46–51.

69. Merritt BK, Stee MJ, Thalacker-Mercer A, Windham ST, Cross JM, Shelley DP, et al. Heightened muscle inflammation susceptibility may impair regenerative capacity in aging humans. J Appl Physiol. 2013;115:937–48.

70. McKay BR, Ogborn DI, Baker JM, Toth KG, Tarnopolsky MA, Parise G. Elevated SOCS3 and altered IL-6 signaling is associated with age-related human muscle stem cell dysfunction. Am J Physiol Cell Physiol. 2013;304:C717–28.

71. Raue U, Silinka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol A Biol Sci Med Sci. 2007;62:1407–12.

72. McKay BR, Ogborn DI, Bellamy LM, Tarnopolsky MA, Parise G. Myostatin is associated with age-related human muscle stem cell dysfunction. FASEB J. 2012;26:2509–21.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit